| ￥3500 | |
| Z05908-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Purity |
> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC |
||||||
| Endotoxin Level | Less than 1 EU per μg by the LAL method. | ||||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized TPBG/5T4, His & Avi, Human at 0.5 μg/ml (100 μl/Well) on the plate can bind Anti?TPBG Antibody, hFc Tag. Test result was comparable to standard batch. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 38.2 kDa | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 50-70 kDa based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background | The oncofetal tumor-associated antigen 5T4 (TBGP) has been linked with CSC properties in several different malignancies. 5T4 has functional attributes that are relevant to the spread of tumors including through EMT, CXCR4/CXCL12, Wnt, and Hippo pathways which may all contribute through the mobilization of CSCs. |
| Synonyms | M6P1; 5T4AG; WAIF1; TPBG; 5T4 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
